Assobiotec - English version

21 March 2019

MolMed received the authorization to start phase I/II clinical investigation with CAR T CD44v6 cells in acute myeloid leukemia and multiple myeloma

The authorization from AIFA follows the positive technical opinion expressed by the Italian National Institute of Health – ISS (Istituto Superiore di Sanità) on March 12th, 2019.

Salute

06 March 2019

KETBIO - Novel service checks market potential of biotech research projects

KET-BIO, an initiative to transfer research results to markets, has gone live with a novel online hub for key enabling biotechnology research.

Bioeconomia

28 February 2019

Newron supports an international study to examine the burden of Rett syndrome on patients and caregivers

Newron supports an international study to examine the burden of Rett syndrome on patients and caregivers, featured at Findacure’s Drug Repurposing for Rare Diseases Conference in the UK

13 February 2019

MolMed: Germany confirms the reimbursement of Zalmoxis® at a price of 130,000 Euro per infusion

The agreement will be in force as of February 15th, 2019. Thanks to this agreement, valid for the next 24 months, Zalmoxis® could be prescribed in all the bone marrow transplant centres operating in Germany

22 January 2019

Valeo Pharma and Zambon announce the approval of safinamide for Canada

New treatment option for estimated 100,000 Canadians living with Parkinson's Disease

08 January 2019

DiaSorin launches Simplexa Bordetella Direct molecular test in the United States

DiaSorin received FDA clearance for its new Bordetella molecular diagnostic test designed to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in human nasopharyngeal swabs.

Edition 2019

New report on Life Sciences

News

MolMed received the authorization to start phase I/II clinical investigation with CAR T CD44v6 cells in acute myeloid leukemia and multiple myeloma

KETBIO - Novel service checks market potential of biotech research projects

Newron supports an international study to examine the burden of Rett syndrome on patients and caregivers

MolMed: Germany confirms the reimbursement of Zalmoxis® at a price of 130,000 Euro per infusion

Valeo Pharma and Zambon announce the approval of safinamide for Canada

DiaSorin launches Simplexa Bordetella Direct molecular test in the United States

Partner

Where to find us

Edition 2019

New report on Life Sciences

News

MolMed received the authorization to start phase I/II clinical investigation with CAR T CD44v6 cells in acute myeloid leukemia and multiple myeloma

KETBIO - Novel service checks market potential of biotech research projects

Newron supports an international study to examine the burden of Rett syndrome on patients and caregivers

MolMed: Germany confirms the reimbursement of Zalmoxis® at a price of 130,000 Euro per infusion

Valeo Pharma and Zambon announce the approval of safinamide for Canada

DiaSorin launches Simplexa Bordetella Direct molecular test in the United States

Partner

Where to find us

Our site uses cookies